Vical Inc - logo

Vical Inc - Company & Market Research Reports

Vical Incorporated is a biopharmaceutical company that develops products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Its product candidates include CyMVectin prophylactic vaccine for cytomegalovirus (CMV), a therapeutic vaccine and prophylactic for herpes simplex virus type 2 and VL-2397 antifungal. The company was founded in 1987 and is headquartered in San Diego, California.

Hepatitis Drug Development Pipeline Review, 2018 - Product Thumbnail Image

Hepatitis Drug Development Pipeline Review, 2018

  • Report
  • 133 Pages
From
Herpes Simplex Virus (HSV) Infections Therapeutics Pipeline Analysis, 2017 - Product Thumbnail Image

Herpes Simplex Virus (HSV) Infections Therapeutics Pipeline Analysis, 2017

  • Report
  • 77 Pages
From
Global Herpes Treatment Market 2017-2021 - Product Thumbnail Image

Global Herpes Treatment Market 2017-2021

  • Report
  • 82 Pages
From
Dengue DNA vaccine - Product Thumbnail Image

Dengue DNA vaccine

  • Drug Pipelines
  • 10 Pages
From
Human Vaccines - Global Strategic Business Report - Product Thumbnail Image

Human Vaccines - Global Strategic Business Report

  • Report
  • 380 Pages
From
Global DNA Vaccine Market Insights, Opportunity, Analysis, Market Shares And Forecast 2017 – 2023 - Product Thumbnail Image

Global DNA Vaccine Market Insights, Opportunity, Analysis, Market Shares And Forecast 2017 – 2023

  • Report
  • 190 Pages
From
Global DNA Vaccine Market Research and Forecast, 2018-2023 - Product Thumbnail Image

Global DNA Vaccine Market Research and Forecast, 2018-2023

  • Report
From
Genital Herpes - Market Insights, Epidemiology and Market Forecast - 2027 - Product Thumbnail Image

Genital Herpes - Market Insights, Epidemiology and Market Forecast - 2027

  • Drug Pipelines
  • 130 Pages
From
Herpes Simplex - Market Insight, Epidemiology and Market Forecast - 2027 - Product Thumbnail Image

Herpes Simplex - Market Insight, Epidemiology and Market Forecast - 2027

  • Drug Pipelines
  • 169 Pages
From
Genital Herpes - Pipeline Review, H2 2018 - Product Thumbnail Image

Genital Herpes - Pipeline Review, H2 2018

  • Drug Pipelines
  • 83 Pages
From
Hepatitis B - Pipeline Review, H1 2018 - Product Thumbnail Image

Hepatitis B - Pipeline Review, H1 2018

  • Drug Pipelines
  • 365 Pages
From
Genital Herpes - Pipeline Review, H1 2018 - Product Thumbnail Image

Genital Herpes - Pipeline Review, H1 2018

  • Drug Pipelines
  • 88 Pages
From
Aspergillosis Drug Development Pipeline Study, H2 2018 - Product Thumbnail Image

Aspergillosis Drug Development Pipeline Study, H2 2018

  • Report
  • 90 Pages
From
Herpes Simplex Virus Treatment - Global Strategic Business Report - Product Thumbnail Image

Herpes Simplex Virus Treatment - Global Strategic Business Report

  • Report
  • 300 Pages
From
Herpes Simplex Infections - Pipeline Review, H2 2015 - Product Thumbnail Image

Herpes Simplex Infections - Pipeline Review, H2 2015

  • Drug Pipelines
  • 185 Pages
From
Herpes Simplex Virus (HSV) Infections - Pipeline Review, H1 2016 - Product Thumbnail Image

Herpes Simplex Virus (HSV) Infections - Pipeline Review, H1 2016

  • Drug Pipelines
  • 177 Pages
From
Cancer Vaccines: Technologies and Global Markets - Product Thumbnail Image

Cancer Vaccines: Technologies and Global Markets

  • Report
  • 183 Pages
From
Herpes Simplex Infections - Pipeline Review, H1 2015 - Product Thumbnail Image

Herpes Simplex Infections - Pipeline Review, H1 2015

  • Drug Pipelines
  • 188 Pages
From
Aspergillosis R&D Pipeline Analysis Report, H2-2018 - Product Thumbnail Image

Aspergillosis R&D Pipeline Analysis Report, H2-2018

  • Report
  • 100 Pages
From
Aspergillosis - Pipeline Review, H2 2018 - Product Thumbnail Image

Aspergillosis - Pipeline Review, H2 2018

  • Drug Pipelines
  • 140 Pages
From
Loading Indicator
adroll